Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial

IMPORTANCE: Ubrogepant is an oral calcitonin gene–related peptide receptor antagonist under investigation for acute treatment of migraine. OBJECTIVE: To evaluate the efficacy and tolerability of ubrogepant compared with placebo for acute treatment of a single migraine attack. DESIGN, SETTING, AND PA...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :JAMA
Главные авторы: Lipton, Richard B., Dodick, David W., Ailani, Jessica, Lu, Kaifeng, Finnegan, Michelle, Szegedi, Armin, Trugman, Joel M.
Формат: Artigo
Язык:Inglês
Опубликовано: American Medical Association 2019
Предметы:
Original Investigation
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6865323/
https://ncbi.nlm.nih.gov/pubmed/31742631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2019.16711
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы